Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
NEW YORK, April 30, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the expansion of its Equity Research platform with the appointment of Caroline Palomeque as a Senior Vice President and Senior Biotechnology Analyst.
Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also coauthored several scientific papers which were peer-reviewed academic journals. “I am pleased to add someone with Caroline’s experience background to our Healthcare Platform. Healthcare is a core vertical at Maxim Group and Biotechnology is an important component,” said Anthony V. Vendetti, Executive Managing Director and Head of Equity Research at Maxim Group.
Ms. Palomeque holds an M.B.A. in Finance from Fordham University Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
